Clinical Trial Update: Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating first-line combination therapy with osimertinib and tegavivint for metastatic EGFR-mutant non-small cell lung cancer; the st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• TAGRISSO (osimertinib)
• Tegavivint

Snippet

Sponsor: Ohio State University Comprehensive Cancer Center | Conditions: Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 | Phase 1 | Status: RECRUITING